<DOC>
	<DOCNO>NCT00648193</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's paroxetine hydrochloride 40 mg tablet GSK 's Paxil® 40 mg tablet follow single , oral 40 mg ( 1 x 40 mg ) dose administer fasting condition healthy adult volunteer .</brief_summary>
	<brief_title>Fasting Study Paroxetine Hydrochloride Tablets 40 mg Paxil® Tablets 40 mg</brief_title>
	<detailed_description />
	<mesh_term>Paroxetine</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male and/or female nonchildbearing potential . 1 . Women consider childbearing potential one follow report documented medical history : 1. postmenopausal absence menses least one ( 1 ) year , 2. bilateral oophorectomy without hysterectomy absence bleed least 6 month , 3. total hysterectomy absence bleed least three month 2 . During course study , study screen study exit include washout period , men must use spermicide contain barrier method contraception ( i.e . condom contain spermicide ) . This advice document informed consent form . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject Body Mass Index ( BMI ) less equal 30 great equal 19 ( see Part II , Administrative Aspects Bioequivalence Protocols ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , Hepatitis B Hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 21 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobaccocontaining product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . 3 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Use monoamine oxidase inhibitor ( MAOIs ) , pimozide , thioridazine within 30 day prior initial dose study medication . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , Hepatitis B , Hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity paroxetine relate product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration . 11 . History depression , mania , seizure , akathisia , narrow angle glaucoma , and/or suicidal ideation behavior ( suicidality ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>